Outcomes in COVID-19 nitazoxanide studies
0
0.5
1
1.5+
All studies
33%
13
3,606
Improvement, Studies, Patients
Relative Risk
Mortality
42%
6
1,877
Ventilation
82%
3
588
ICU admission
28%
3
841
Hospitalization
61%
6
1,864
Progression
-120%
2
981
Recovery
1%
5
1,309
Cases
17%
1
505
Viral clearance
38%
7
865
RCTs
8%
10
2,955
RCT mortality
28%
4
1,339
Peer-reviewed
54%
10
2,608
Prophylaxis
66%
1
505
Early
29%
8
2,545
Late
12%
4
556
Nitazoxanide for COVID-19
c19 early.org/n Feb 2023
Favors nitazoxanide
Favors control
after exclusions
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI]
Treatment
Control
Cadegiani
88%
0.12 [0.01-2.52]
death
0/357
2/137
Elalfy
87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT2
Silva (SB RCT)
26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
ANTICOV
ANTICOV (RCT)
-188%
2.88 [1.05-7.85]
progression
15/462
5/443
OT1 CT2
Rossignol (DB RCT)
-206%
3.06 [0.13-74.6]
death
1/184
0/195
Medhat (RCT)
56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Chandiwana (RCT)
-13%
1.13 [0.23-5.46]
progression
37 (n)
39 (n)
CT2
Tau2 = 1.04, I2 = 78.3%, p = 0.46
Early treatment
29%
0.71 [0.29-1.73]
25/1,396
51/1,149
29% improvement
Blum (DB RCT)
67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI]
Treatment
Control
Calderón
68%
0.32 [0.04-2.49]
death
1/17
5/27
OT1
Fowotade (RCT)
-11%
1.11 [0.61-2.03]
no recov.
31 (n)
26 (n)
CT2
Rocco (DB RCT)
-5%
1.05 [0.30-3.50]
death
6/202
5/203
Tau2 = 0.03, I2 = 7.9%, p = 0.65
Late treatment
12%
0.88 [0.52-1.50]
9/275
16/281
12% improvement
COVER
Sokhela (RCT)
66%
0.34 [0.01-8.41]
death
0/240
1/265
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.52
Prophylaxis
66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement
All studies
33%
0.67 [0.37-1.22]
34/1,911
68/1,695
33% improvement
13 nitazoxanide COVID-19 studies
c19 early.org/n Feb 2023
Tau2 = 0.66, I2 = 69.4%, p = 0.19
Effect extraction pre-specified (most serious outcome)
1 OT: comparison with other treatment 2 CT: study uses combined treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI]
Treatment
Control
Cadegiani
88%
0.12 [0.01-2.52]
death
0/357
2/137
Elalfy
87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT2
Silva (SB RCT)
26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
Rossignol (DB RCT)
-206%
3.06 [0.13-74.6]
death
1/184
0/195
Medhat (RCT)
56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Chandiwana (RCT)
-13%
1.13 [0.23-5.46]
progression
37 (n)
39 (n)
CT2
Tau2 = 0.67, I2 = 69.3%, p = 0.12
Early treatment
49%
0.51 [0.22-1.18]
10/934
46/706
49% improvement
Blum (DB RCT)
67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI]
Treatment
Control
Calderón
68%
0.32 [0.04-2.49]
death
1/17
5/27
OT1
Fowotade (RCT)
-11%
1.11 [0.61-2.03]
no recov.
31 (n)
26 (n)
CT2
Rocco (DB RCT)
-5%
1.05 [0.30-3.50]
death
6/202
5/203
Tau2 = 0.03, I2 = 7.9%, p = 0.65
Late treatment
12%
0.88 [0.52-1.50]
9/275
16/281
12% improvement
COVER
Sokhela (RCT)
66%
0.34 [0.01-8.41]
death
0/240
1/265
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.52
Prophylaxis
66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement
All studies
44%
0.56 [0.32-1.01]
19/1,449
63/1,252
44% improvement
12 nitazoxanide COVID-19 studies after exclusions
c19 early.org/n Feb 2023
Tau2 = 0.50, I2 = 63.0%, p = 0.052
Effect extraction pre-specified (most serious outcome)
1 OT: comparison with other treatment 2 CT: study uses combined treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani
88%
0.12 [0.01-2.52]
0/357
2/137
Improvement, RR [CI]
Treatment
Control
Rossignol (DB RCT)
-206%
3.06 [0.13-74.6]
1/184
0/195
Tau2 = 2.67, I2 = 51.4%, p = 0.75
Early treatment
41%
0.59 [0.02-13.8]
1/541
2/332
41% improvement
Blum (DB RCT)
67%
0.33 [0.07-1.50]
2/25
6/25
Improvement, RR [CI]
Treatment
Control
Calderón
68%
0.32 [0.04-2.49]
1/17
5/27
OT1
Rocco (DB RCT)
-5%
1.05 [0.30-3.50]
6/202
5/203
Tau2 = 0.00, I2 = 0.0%, p = 0.23
Late treatment
40%
0.60 [0.26-1.39]
9/244
16/255
40% improvement
COVER
Sokhela (RCT)
66%
0.34 [0.01-8.41]
0/240
1/265
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.52
Prophylaxis
66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement
All studies
42%
0.58 [0.27-1.24]
10/1,025
19/852
42% improvement
6 nitazoxanide COVID-19 mortality results
c19 early.org/n Feb 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.16
1 OT: comparison with other treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani
97%
0.03 [0.00-0.51]
0/357
9/137
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.015
Early treatment
97%
0.03 [0.00-0.51]
0/357
9/137
97% improvement
Blum (DB RCT)
62%
0.38 [0.11-1.25]
3/25
8/25
Improvement, RR [CI]
Treatment
Control
Calderón
87%
0.13 [0.01-2.33]
0/17
4/27
OT1
Tau2 = 0.00, I2 = 0.0%, p = 0.044
Late treatment
68%
0.32 [0.11-0.97]
3/42
12/52
68% improvement
All studies
82%
0.18 [0.04-0.76]
3/399
21/189
82% improvement
3 nitazoxanide COVID-19 mechanical ventilation results
c19 early.org/n Feb 2023
Tau2 = 0.50, I2 = 27.5%, p = 0.019
1 OT: comparison with other treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-404%
5.04 [0.24-104]
2/194
0/198
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.3
Early treatment
-404%
5.04 [0.24-104]
2/194
0/198
-404% improvement
Calderón
59%
0.41 [0.25-0.59]
0/17
16/27
OT1
Improvement, RR [CI]
Treatment
Control
Rocco (DB RCT)
31%
0.69 [0.40-1.17]
20/202
30/203
Tau2 = 0.00, I2 = 0.0%, p = 0.15
Late treatment
32%
0.68 [0.40-1.15]
20/219
46/230
32% improvement
All studies
28%
0.72 [0.43-1.21]
22/413
46/428
28% improvement
3 nitazoxanide COVID-19 ICU results
c19 early.org/n Feb 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.22
1 OT: comparison with other treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-2%
1.02 [0.30-3.47]
hosp.
5/194
5/198
Improvement, RR [CI]
Treatment
Control
Cadegiani
99%
0.01 [0.00-0.17]
hosp.
0/357
27/137
Rossignol (DB RCT)
79%
0.21 [0.02-1.80]
hosp.
1/184
5/195
Tau2 = 3.68, I2 = 78.4%, p = 0.16
Early treatment
83%
0.17 [0.01-2.00]
6/735
37/530
83% improvement
Blum (DB RCT)
56%
0.44 [0.22-0.89]
hosp. time
25 (n)
25 (n)
Improvement, RR [CI]
Treatment
Control
Calderón
52%
0.48 [0.29-0.82]
hosp. time
17 (n)
27 (n)
OT1
Tau2 = 0.00, I2 = 0.0%, p = 0.0004
Late treatment
53%
0.47 [0.31-0.71]
0/42
0/52
53% improvement
COVER
Sokhela (RCT)
79%
0.21 [0.01-4.31]
hosp.
0/240
2/265
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.31
Prophylaxis
79%
0.21 [0.01-4.31]
0/240
2/265
79% improvement
All studies
61%
0.39 [0.20-0.78]
6/1,017
39/847
61% improvement
6 nitazoxanide COVID-19 hospitalization results
c19 early.org/n Feb 2023
Tau2 = 0.29, I2 = 47.9%, p = 0.0078
1 OT: comparison with other treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI]
Treatment
Control
Cadegiani
88%
0.12 [0.01-2.52]
death
0/357
2/137
ANTICOV
ANTICOV (RCT)
-188%
2.88 [1.05-7.85]
progression
15/462
5/443
OT1 CT2
Rossignol (DB RCT)
-206%
3.06 [0.13-74.6]
death
1/184
0/195
Chandiwana (RCT)
-13%
1.13 [0.23-5.46]
progression
37 (n)
39 (n)
CT2
Tau2 = 0.18, I2 = 15.0%, p = 0.2
Early treatment
-82%
1.82 [0.73-4.53]
18/1,234
7/1,012
-82% improvement
Blum (DB RCT)
67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI]
Treatment
Control
Calderón
68%
0.32 [0.04-2.49]
death
1/17
5/27
OT1
Rocco (DB RCT)
-5%
1.05 [0.30-3.50]
death
6/202
5/203
Tau2 = 0.00, I2 = 0.0%, p = 0.23
Late treatment
40%
0.60 [0.26-1.39]
9/244
16/255
40% improvement
COVER
Sokhela (RCT)
66%
0.34 [0.01-8.41]
death
0/240
1/265
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.52
Prophylaxis
66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement
All studies
2%
0.98 [0.47-2.01]
27/1,718
24/1,532
2% improvement
9 nitazoxanide COVID-19 serious outcomes
c19 early.org/n Feb 2023
Tau2 = 0.33, I2 = 28.9%, p = 0.95
Effect extraction pre-specified (most serious outcome)
1 OT: comparison with other treatment 2 CT: study uses combined treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-16%
1.16 [0.84-1.59]
no recov.
59/194
52/198
Improvement, RR [CI]
Treatment
Control
Rossignol (DB RCT)
-7%
1.07 [0.46-2.49]
recov. time
184 (n)
195 (n)
Chandiwana (RCT)
-23%
1.23 [0.73-2.08]
recov. time
37 (n)
39 (n)
CT1
Tau2 = 0.00, I2 = 0.0%, p = 0.23
Early treatment
-17%
1.17 [0.91-1.51]
59/415
52/432
-17% improvement
Fowotade (RCT)
-11%
1.11 [0.61-2.03]
no recov.
31 (n)
26 (n)
CT1
Improvement, RR [CI]
Treatment
Control
Rocco (DB RCT)
27%
0.73 [0.58-0.90]
no disch.
202 (n)
203 (n)
Tau2 = 0.04, I2 = 45.6%, p = 0.33
Late treatment
17%
0.83 [0.57-1.21]
0/233
0/229
17% improvement
All studies
1%
0.99 [0.76-1.30]
59/648
52/661
1% improvement
5 nitazoxanide COVID-19 recovery results
c19 early.org/n Feb 2023
Tau2 = 0.04, I2 = 51.6%, p = 0.95
1 CT: study uses combined treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
COVER
Sokhela (RCT)
17%
0.83 [0.50-1.40]
symp. case
23/240
37/265
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.47
Prophylaxis
17%
0.83 [0.50-1.40]
23/240
37/265
17% improvement
All studies
17%
0.83 [0.51-1.36]
23/240
37/265
17% improvement
1 nitazoxanide COVID-19 case result
c19 early.org/n Feb 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.47
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
12%
0.88 [0.80-0.96]
viral+
194 (n)
198 (n)
Improvement, RR [CI]
Treatment
Control
Elalfy
87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT1
Silva (SB RCT)
26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
Medhat (RCT)
56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Chandiwana (RCT)
-67%
1.67 [0.85-3.23]
viral+
27/37
25/38
CT1
Tau2 = 0.37, I2 = 91.9%, p = 0.11
Early treatment
38%
0.62 [0.35-1.11]
34/393
69/373
38% improvement
Blum (DB RCT)
90%
0.10 [0.01-1.78]
viral+
0/23
4/19
Improvement, RR [CI]
Treatment
Control
Fowotade (RCT)
5%
0.95 [0.34-2.64]
viral load
31 (n)
26 (n)
CT1
Tau2 = 1.31, I2 = 52.6%, p = 0.48
Late treatment
53%
0.47 [0.06-3.59]
0/54
4/45
53% improvement
All studies
38%
0.62 [0.37-1.05]
34/447
73/418
38% improvement
7 nitazoxanide COVID-19 viral clearance results
c19 early.org/n Feb 2023
Tau2 = 0.35, I2 = 88.3%, p = 0.076
1 CT: study uses combined treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI]
Treatment
Control
Silva (SB RCT)
26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
ANTICOV
ANTICOV (RCT)
-188%
2.88 [1.05-7.85]
progression
15/462
5/443
OT1 CT2
Rossignol (DB RCT)
-206%
3.06 [0.13-74.6]
death
1/184
0/195
Medhat (RCT)
56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Chandiwana (RCT)
-13%
1.13 [0.23-5.46]
progression
37 (n)
39 (n)
CT2
Tau2 = 0.39, I2 = 56.0%, p = 0.87
Early treatment
-7%
1.07 [0.51-2.23]
18/977
5/961
-7% improvement
Blum (DB RCT)
67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI]
Treatment
Control
Fowotade (RCT)
-11%
1.11 [0.61-2.03]
no recov.
31 (n)
26 (n)
CT2
Rocco (DB RCT)
-5%
1.05 [0.30-3.50]
death
6/202
5/203
Tau2 = 0.03, I2 = 8.5%, p = 0.86
Late treatment
5%
0.95 [0.55-1.63]
8/258
11/254
5% improvement
COVER
Sokhela (RCT)
66%
0.34 [0.01-8.41]
death
0/240
1/265
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.52
Prophylaxis
66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement
All studies
8%
0.92 [0.59-1.43]
26/1,475
17/1,480
8% improvement
10 nitazoxanide COVID-19 Randomized Controlled Trials
c19 early.org/n Feb 2023
Tau2 = 0.16, I2 = 36.1%, p = 0.72
Effect extraction pre-specified (most serious outcome)
1 OT: comparison with other treatment 2 CT: study uses combined treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rossignol (DB RCT)
-206%
3.06 [0.13-74.6]
1/184
0/195
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.5
Early treatment
-206%
3.06 [0.13-74.6]
1/184
0/195
-206% improvement
Blum (DB RCT)
67%
0.33 [0.07-1.50]
2/25
6/25
Improvement, RR [CI]
Treatment
Control
Rocco (DB RCT)
-5%
1.05 [0.30-3.50]
6/202
5/203
Tau2 = 0.19, I2 = 28.2%, p = 0.46
Late treatment
35%
0.65 [0.22-1.98]
8/227
11/228
35% improvement
COVER
Sokhela (RCT)
66%
0.34 [0.01-8.41]
0/240
1/265
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.52
Prophylaxis
66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement
All studies
28%
0.72 [0.31-1.70]
9/651
12/688
28% improvement
4 nitazoxanide COVID-19 RCT mortality results
c19 early.org/n Feb 2023
Tau2 = 0.00, I2 = 0.0%, p = 0.46
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI]
Treatment
Control
Cadegiani
88%
0.12 [0.01-2.52]
death
0/357
2/137
Elalfy
87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT2
Rossignol (DB RCT)
-206%
3.06 [0.13-74.6]
death
1/184
0/195
Medhat (RCT)
56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Chandiwana (RCT)
-13%
1.13 [0.23-5.46]
progression
37 (n)
39 (n)
CT2
Tau2 = 0.85, I2 = 66.6%, p = 0.16
Early treatment
52%
0.48 [0.17-1.34]
10/911
46/693
52% improvement
Blum (DB RCT)
67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI]
Treatment
Control
Calderón
68%
0.32 [0.04-2.49]
death
1/17
5/27
OT1
Rocco (DB RCT)
-5%
1.05 [0.30-3.50]
death
6/202
5/203
Tau2 = 0.00, I2 = 0.0%, p = 0.23
Late treatment
40%
0.60 [0.26-1.39]
9/244
16/255
40% improvement
COVER
Sokhela (RCT)
66%
0.34 [0.01-8.41]
death
0/240
1/265
Improvement, RR [CI]
Treatment
Control
Tau2 = 0.00, I2 = 0.0%, p = 0.52
Prophylaxis
66%
0.34 [0.01-8.41]
0/240
1/265
66% improvement
All studies
54%
0.46 [0.23-0.93]
19/1,395
63/1,213
54% improvement
10 nitazoxanide COVID-19 peer reviewed studies
c19 early.org/n Feb 2023
Tau2 = 0.52, I2 = 51.7%, p = 0.03
Effect extraction pre-specified (most serious outcome)
1 OT: comparison with other treatment 2 CT: study uses combined treatment
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT)
-404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI]
Treatment
Control
Rocco (RCT)
-2%
1.02 [0.30-3.47]
hosp.
5/194
5/198
Rocco (RCT)
-16%
1.16 [0.84-1.59]
no recov.
59/194
52/198
Rocco (RCT)
12%
0.88 [0.80-0.96]
viral+
194 (n)
198 (n)
Rocco (RCT)
14%
0.86 [0.77-0.96]
viral+
136/194
162/198
Cadegiani
88%
0.12 [0.01-2.52]
death
0/357
2/137
Cadegiani
97%
0.03 [0.00-0.51]
ventilation
0/357
9/137
Cadegiani
99%
0.01 [0.00-0.17]
hosp.
0/357
27/137
Elalfy
87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT2
Elalfy
58%
0.42 [0.31-0.56]
viral+
26/62
51/51
CT2
Silva (SB RCT)
26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
Silva (SB RCT)
38%
0.62 [0.36-1.05]
viral+
12/23
11/13
ANTICOV
ANTICOV (RCT)
-188%
2.88 [1.05-7.85]
progression
15/462
5/443
OT1 CT2
Rossignol (DB RCT)
-206%
3.06 [0.13-74.6]
death
1/184
0/195
Rossignol (DB RCT)
79%
0.21 [0.02-1.80]
hosp.
1/184
5/195
Rossignol (DB RCT)
85%
0.15 [0.02-1.22]
severe case
1/184
7/195
Rossignol (DB RCT)
84%
0.16 [0.02-1.29]
severe case
1/112
7/126
Rossignol (DB RCT)
-7%
1.07 [0.46-2.49]
recov. time
184 (n)
195 (n)
Medhat (RCT)
56%
0.44 [0.22-0.88]
viral+
77 (n)
73 (n)
Chandiwana (RCT)
-13%
1.13 [0.23-5.46]
progression
37 (n)
39 (n)
CT2
Chandiwana (RCT)
-23%
1.23 [0.73-2.08]
recov. time
37 (n)
39 (n)
CT2
Chandiwana (RCT)
-67%
1.67 [0.85-3.23]
viral+
27/37
25/38
CT2
Blum (DB RCT)
67%
0.33 [0.07-1.50]
death
2/25
6/25
Blum (DB RCT)
62%
0.38 [0.11-1.25]
ventilation
3/25
8/25
Blum (DB RCT)
56%
0.44 [0.22-0.89]
hosp. time
25 (n)
25 (n)
Blum (DB RCT)
90%
0.10 [0.01-1.78]
viral+
0/23
4/19
Calderón
68%
0.32 [0.04-2.49]
death
1/17
5/27
OT1
Calderón
87%
0.13 [0.01-2.33]
ventilation
0/17
4/27
OT1
Calderón
59%
0.41 [0.25-0.59]
ICU
0/17
16/27
OT1
Calderón
52%
0.48 [0.29-0.82]
hosp. time
17 (n)
27 (n)
OT1
Fowotade (RCT)
-11%
1.11 [0.61-2.03]
no recov.
31 (n)
26 (n)
CT2
Fowotade (RCT)
-87%
1.87 [0.88-3.98]
no recov.
31 (n)
26 (n)
CT2
Fowotade (RCT)
5%
0.95 [0.34-2.64]
viral load
31 (n)
26 (n)
CT2
Rocco (DB RCT)
-5%
1.05 [0.30-3.50]
death
6/202
5/203
Rocco (DB RCT)
31%
0.69 [0.40-1.17]
ICU
20/202
30/203
Rocco (DB RCT)
40%
0.60 [0.35-1.02]
oxygen
22/202
33/203
Rocco (DB RCT)
64%
0.36 [0.29-0.45]
no improv.
202 (n)
203 (n)
Rocco (DB RCT)
34%
0.66 [0.38-1.15]
no improv.
202 (n)
203 (n)
Rocco (DB RCT)
27%
0.73 [0.58-0.90]
no disch.
202 (n)
203 (n)
Rocco (DB RCT)
8%
0.92 [0.55-1.52]
no disch.
202 (n)
203 (n)
COVER
Sokhela (RCT)
66%
0.34 [0.01-8.41]
death
0/240
1/265
COVER
Sokhela (RCT)
79%
0.21 [0.01-4.31]
hosp.
0/240
2/265
COVER
Sokhela (RCT)
17%
0.83 [0.50-1.40]
symp. case
23/240
37/265
COVER
Sokhela (RCT)
-21%
1.21 [0.29-1.58]
cases
23/240
37/265
Nitazoxanide COVID-19 outcomes
c19 early.org/n Feb 2023
1 OT: comparison with other treatment 2 CT: study uses combined treatment
Favors nitazoxanide
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit